195 related articles for article (PubMed ID: 31586640)
1. The impact of steroids on the injured podocytes in nephrotic syndrome.
Hosseiniyan Khatibi SM; Ardalan M; Abediazar S; Zununi Vahed S
J Steroid Biochem Mol Biol; 2020 Feb; 196():105490. PubMed ID: 31586640
[TBL] [Abstract][Full Text] [Related]
2. Salvianolic acid A attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-αvβ3 signaling Inhibition.
Li X; Qi D; Wang MY; Ji K; Xie QL; Wang Y; Du SH; Fan HY
J Ethnopharmacol; 2021 Oct; 279():114351. PubMed ID: 34157324
[TBL] [Abstract][Full Text] [Related]
3. Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into mechanisms of action via direct action on the kidney podocyte.
Jiang L; Dasgupta I; Hurcombe JA; Colyer HF; Mathieson PW; Welsh GI
Clin Sci (Lond); 2015 Jun; 128(12):883-93. PubMed ID: 25626449
[TBL] [Abstract][Full Text] [Related]
4. The podocyte as a direct target of glucocorticoids in nephrotic syndrome.
Broek MVD; Smeets B; Schreuder MF; Jansen J
Nephrol Dial Transplant; 2022 Sep; 37(10):1808-1815. PubMed ID: 33515261
[TBL] [Abstract][Full Text] [Related]
5. Steroid-resistant nephrotic syndrome: pharmacogenetics and epigenetic points and views.
Hejazian SM; Zununi Vahed S; Moghaddas Sani H; Nariman-Saleh-Fam Z; Bastami M; Hosseiniyan Khatibi SM; Ardalan M; Samadi N
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):147-156. PubMed ID: 31847609
[No Abstract] [Full Text] [Related]
6. Podocyte Sphingolipid Signaling in Nephrotic Syndrome.
Li G; Kidd J; Gehr TWB; Li PL
Cell Physiol Biochem; 2021 Apr; 55(S4):13-34. PubMed ID: 33861526
[TBL] [Abstract][Full Text] [Related]
7. Mutations in KIRREL1, a slit diaphragm component, cause steroid-resistant nephrotic syndrome.
Solanki AK; Widmeier E; Arif E; Sharma S; Daga A; Srivastava P; Kwon SH; Hugo H; Nakayama M; Mann N; Majmundar AJ; Tan W; Gee HY; Sadowski CE; Rinat C; Becker-Cohen R; Bergmann C; Rosen S; Somers M; Shril S; Huber TB; Mane S; Hildebrandt F; Nihalani D
Kidney Int; 2019 Oct; 96(4):883-889. PubMed ID: 31472902
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1.
McCaffrey JC; Webb NJ; Poolman TM; Fresquet M; Moxey C; Zeef LAH; Donaldson IJ; Ray DW; Lennon R
Sci Rep; 2017 Jul; 7(1):6725. PubMed ID: 28751734
[TBL] [Abstract][Full Text] [Related]
9. Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury.
Zhou H; Tian X; Tufro A; Moeckel G; Ishibe S; Goodwin J
Sci Rep; 2017 Aug; 7(1):9833. PubMed ID: 28852159
[TBL] [Abstract][Full Text] [Related]
10. Steroid-resistant Nephrotic Syndrome in Children: A Mini-review on Genetic Mechanisms, Predictive Biomarkers and Pharmacotherapy Strategies.
Guo HL; Li L; Xu ZY; Jing X; Xia Y; Qiu JC; Ji X; Chen F; Xu J; Zhao F
Curr Pharm Des; 2021; 27(2):319-329. PubMed ID: 33138756
[TBL] [Abstract][Full Text] [Related]
11. Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology.
Dogra S; Kaskel F
Pediatr Nephrol; 2017 Jun; 32(6):965-974. PubMed ID: 27783158
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid treatment exacerbates nephrotic syndrome in a zebrafish model of magi2a knockout.
Jobst-Schwan T; Hoogstraten CA; Kolvenbach CM; Schmidt JM; Kolb A; Eddy K; Schneider R; Ashraf S; Widmeier E; Majmundar AJ; Hildebrandt F
Kidney Int; 2019 May; 95(5):1079-1090. PubMed ID: 31010479
[TBL] [Abstract][Full Text] [Related]
13. The Role of Glucocorticoid Receptors in Podocytes and Nephrotic Syndrome.
Zhao X; Hwang DY; Kao HY
Nucl Receptor Res; 2018; 5():. PubMed ID: 30417008
[TBL] [Abstract][Full Text] [Related]
14. Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?
Müller-Deile J; Schiffer M
Pediatr Nephrol; 2016 Mar; 31(3):393-405. PubMed ID: 25939817
[TBL] [Abstract][Full Text] [Related]
15. Circulating extracellular vesicles of patients with steroid-sensitive nephrotic syndrome have higher RAC1 and induce recapitulation of nephrotic syndrome phenotype in podocytes.
Eroglu FK; Yazar V; Guler U; Yıldırım M; Yildirim T; Gungor T; Celikkaya E; Karakaya D; Turay N; Ciftci Dede E; Korkusuz P; Salih B; Bulbul M; Gursel I
Am J Physiol Renal Physiol; 2021 Nov; 321(5):F659-F673. PubMed ID: 34569252
[TBL] [Abstract][Full Text] [Related]
16. Use of genomic and functional analysis to characterize patients with steroid-resistant nephrotic syndrome.
Kitzler TM; Kachurina N; Bitzan MM; Torban E; Goodyer PR
Pediatr Nephrol; 2018 Oct; 33(10):1741-1750. PubMed ID: 29982877
[TBL] [Abstract][Full Text] [Related]
17. Qi-Dan Fang ameliorates adriamycin-induced nephrotic syndrome rat model by enhancing renal function and inhibiting podocyte injury.
Wu JB; Ye SF; Liang CL; Li YC; Yu YJ; Lai JM; Lin H; Zheng J; Zhou JY
J Ethnopharmacol; 2014 Feb; 151(3):1124-1132. PubMed ID: 24389029
[TBL] [Abstract][Full Text] [Related]
18. The podocyte as a direct target of immunosuppressive agents.
Schönenberger E; Ehrich JH; Haller H; Schiffer M
Nephrol Dial Transplant; 2011 Jan; 26(1):18-24. PubMed ID: 20937691
[TBL] [Abstract][Full Text] [Related]
19. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids.
Youssef DM; Attia TA; El-Shal AS; Abduelometty FA
Gene; 2013 Nov; 530(2):201-7. PubMed ID: 23994685
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.
Schijvens AM; Ter Heine R; de Wildt SN; Schreuder MF
Pediatr Nephrol; 2019 Mar; 34(3):389-403. PubMed ID: 29549463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
